Adeptus Health, Juno Therapeutics, Puma Biotechnology News Today

Adeptus Health Inc (ADPT), Juno Therapeutics Inc (JUNO), and ​Puma Biotechnology Inc (PBYI) are three stocks in the news today

Mar 2, 2017 at 9:29 AM
facebook twitter linkedin


The Dow is headed for higher highs this morning, set to extend yesterday's quest for uncharted territory. Among specific equities in focus are ER operator Adeptus Health Inc (NYSE:ADPT), as well as drug stocks Juno Therapeutics Inc (NASDAQ:JUNO) and Puma Biotechnology Inc (NASDAQ:PBYI). Here's a quick look at what's moving shares of ADPT, JUNO, and PBYI.

Adeptus Health Heading For Record Lows

ADPT is bracing for a 33% tumble out of the gate, after the company filed for a non-timely 10-K, requiring more time to complete its financial closing procedures for 2016. As a result, the stock -- which settled yesterday at $6.55 -- will likely hit an all-time low out of the gate. Options traders have been counting on extended losses for Adeptus Health Inc shares. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock has amassed a 10-day put/call volume ratio of 8.47 -- ranking just 3 percentage points from an annual high.

Juno Therapeutics Shutters Drug Trial, Suffers Q4 Loss

JUNO will likely snap its three-day rally in a big way, after the drugmaker said it would end development of an experimental leukemia treatment following a series of deaths. This, combined with a wider-than-expected quarterly loss -- and despite a price-target hike to $27 from $25 at Morgan Stanley -- has the stock down 7.2% pre-market. Overall, it's been a dreadful year for Juno Therapeutics Inc, which has shed nearly 37% in the past 12 months to land at $25.31. Short sellers have understandably been active toward the underperformer, with about one-quarter of JUNO's float currently sold short.

Roche Data Drops Puma Biotechnology Shares

PBYI is pointed 25% lower ahead of the open, as rival Roche released positive breast cancer drug results, turning up the competitive pressure for its own drug, neratinib. RBC's massive price-target cut to $17 from $48 -- in four-year low territory -- is also weighing on Puma Biotechnology Inc, overshadowing the company's narrower-than-forecast fourth-quarter loss. Yesterday, the stock settled at $38.05, down 17.8% year-over-year. Another move lower would be a boon to short sellers. Short interest rose 9% in the latest reporting period, and accounts for 26% of PBYI's float, translating into two weeks' worth of trading activity, based on the stock's average daily volume.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

Bernie's Best Stock Bets for Summer 2021

1608308875

 




 
Special Offers from Schaeffer's Trading Partners